Skip to main
COYA
COYA logo

COYA Stock Forecast & Price Target

COYA Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Coya Therapeutics Inc. is demonstrating promising progress with its lead product, COYA 302, which continues to show both safety and efficacy in upcoming Phase 2 trials, indicating a modest superiority over current treatment approaches. Additionally, the anticipated results from the planned Phase 2 clinical trial for ALS suggest a strong clinical benefit, particularly in terms of potentially freezing the progression of the ALSFRS-R scale, which could pave the way for regulatory approval. The insights from key opinion leaders regarding the therapeutic potential of low-dose IL-2 combined with semaglutide further bolster the likelihood of successful outcomes in treating Alzheimer's disease patients.

Bears say

Coya Therapeutics Inc. operates in a high-risk sector characterized by significant uncertainties surrounding clinical trials, regulatory approval processes, and potential safety concerns, which could adversely affect investor confidence and stock performance. Historical data indicate that trial results for conditions like frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) show only modest disease stabilization, raising questions about the efficacy and long-term viability of Coya's therapeutic approaches. Additionally, the complexity of the market, coupled with the price sensitivity of its product candidates, heightens the challenges the company faces in achieving commercial success and profitability.

COYA has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Coya Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Coya Therapeutics Inc (COYA) Forecast

Analysts have given COYA a Strong Buy based on their latest research and market trends.

According to 5 analysts, COYA has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Coya Therapeutics Inc (COYA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.